OR WAIT 15 SECS
The companies will work together to produce a wearable device that can subcutaneously deliver ketamine therapy as a non-opioid pain treatment.
Stevanato Group, an Italian glass primary packaging producer, announced on Sept. 21, 2020 that it has signed an agreement with Bexson Biomedical, a research-stage company, for the development of the SG EZ-be Pod, a wearable drug delivery device for Bexson’s proprietary ketamine formulation, BB106.
Under the terms of the agreement, the companies will work together to produce a small, wearable and programable device that can subcutaneously deliver the ketamine therapy to patients looking for a non-opioid treatment for chronic and acute pain types, a Stevanato press release said.
“In the midst of a pandemic health crisis and evidence of increasing opioid addiction and overdoses, there has never been a greater need for effective non-opioid pain management. Stevanato Group has the ideal technology to deliver Bexson’s BB106 subcutaneous ketamine formulation,” said Gregg Peterson, Bexson’s co-founder and CEO, in the press release. “And beyond pain management, this partnership will create a true ketamine delivery platform that can be leveraged for a large number of future indications.”
“This design will support patient comfort with a discreet and intuitive device, and by utilizing our patented technologies, we address the importance of sustainability, while minimizing the overall cost per treatment,” said Steven Kaufman, vice-president of Drug Delivery Systems, Stevanato Group, in the press release. “This agreement with Bexson is a step forward for our device portfolio strategy and ongoing efforts to work closely with biotech and pharmaceutical companies as an integrated solution provider.”